ERWINAZE® (asparaginase Erwinia chrysanthemi)
- FLASCO
- March 10, 2015
- Drugs
ERWINAZE® (asparaginase Erwinia chrysanthemi)
ERWINAZE® (asparaginase Erwinia chrysanthemi) is now FDA-approved to be administered intravenously (IV) in addition to the originally approved intramuscular (IM) route of administration. ERWINAZE for intramuscular injection (IM) or intravenous infusion (IV), 10,000 International Units/vial is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.
It is important to note that the following information has not changed:
- The J-code (J9019) and J-code units (1,000 IU)
- The NDC number (57902-0249-01)
- Packaging and ordering process
To view the ERWINAZE Product Information Flashcard click here
To view the full ERWINAZE Prescribing Information click here
